天津医药

• 短篇论著 • 上一篇    下一篇

亚砷酸联合维甲酸、化疗治疗急性早幼粒细胞白血病的疗效观察

张燕   

  1. 贵阳医学院附属医院血液内科
  • 收稿日期:2011-10-18 修回日期:2012-07-25 出版日期:2013-01-15 发布日期:2013-01-15
  • 通讯作者: 张燕

Study on the effectiveness of acute promyelocytic leukemia treated with combination therapy( arsenic trioxide with all-trans retinoic acid and chemotherapy)

  • Received:2011-10-18 Revised:2012-07-25 Published:2013-01-15 Online:2013-01-15

PDF (PC)

2784

摘要：

【摘要】 目的观察亚砷酸联合维甲酸、化疗治疗急性早幼粒细胞白血病(APL)的疗效。方法将在我院住院诊治的69例APL患者随机分为治疗组和对照组。治疗组37例,诱导缓解治疗方案为亚砷酸、维甲酸加化疗;对照组32例,治疗方案为维甲酸加化疗,观察2组患者疗效和不良反应。结果治疗组初治诱导缓解治疗完全缓解率为97.2%,高于对照组的87.5%(P<0.05),达完全缓解中位时间为29d,高于对照组的35d,差异有统计学意义(P<0.05)。治疗相关不良反应治疗组与对照组比较差异无统计学意义(P>0.05)。结论亚砷酸联合维甲酸、化疗治疗APL的效果好,安全性高。

关键词: 急性早幼粒细胞白血病, 砷剂, 维甲酸, 治疗

Abstract: Abstract Objective:To observe the effectiveness of arsenic trioxide(AS2O3)associated with all-trans retinoic acid (ATRA )and chemotherapy in treating acute promyelocytic leukemia(APL).Method:69 cases of APL was provided randomly two groups,37 cases in treating group with AS2O3+ATRA+chemotherapy,32 cases in control group with ATRA+ chemotherapy.To observe the effectiveness and side effect. Result:The first induce complete remission(CR)is 96.6% in the treating group,CR is 87.5% in the control group. The bad reaction related to the treatment no significant difference in two groups. Conclusion:Arsenic trioxide(AS2O3)associated with ATRA and chemotherapy had highter curative effect ,The combination is security.

Key words: leukemia promyelocytic acute, Arsenic trioxide, ATRA, Treatment